Nkarta (NASDAQ:NKTX) Issues Quarterly Earnings Results, Misses Estimates By $0.05 EPS

Nkarta (NASDAQ:NKTX) posted its quarterly earnings data on Thursday. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.05), FiscalAI reports.

Nkarta Stock Performance

NKTX traded up $0.16 during trading on Friday, reaching $1.73. The company’s stock had a trading volume of 2,000,682 shares, compared to its average volume of 1,137,618. The company’s fifty day moving average price is $2.34 and its 200-day moving average price is $2.51. Nkarta has a 52-week low of $1.48 and a 52-week high of $3.72. The company has a market capitalization of $123.90 million, a price-to-earnings ratio of -1.00 and a beta of 1.24.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the company. Stifel Nicolaus lowered their target price on Nkarta from $11.00 to $10.00 and set a “buy” rating on the stock in a research note on Friday, August 14th. HC Wainwright started coverage on Nkarta in a report on Monday, November 2nd. They set a “buy” rating for the company. Wall Street Zen lowered shares of Nkarta from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 15th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Nkarta in a research note on Monday, September 21st. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $11.20.

About Nkarta

Nkarta, Inc is a clinical-stage biotechnology company focused on developing engineered natural killer (NK) cell therapies for cancer and autoimmune diseases. The company’s platform is designed to produce allogeneic, or donor-derived, NK cells that can be engineered with chimeric antigen receptors (CARs) to recognize and attack targeted cells.

Nkarta’s research and development programs have included NKX019, a CD19-targeted CAR NK-cell therapy investigated for B-cell malignancies and autoimmune disorders, and NKX101, an NKG2D-targeted CAR NK-cell therapy developed for certain solid tumors.